Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11974083 | 0.97 | AHCY (0.55) | AHCYNOTUM | |
| SCHEMBL11975198 | 0.92 | AHCY (0.47) | AHCYNOTUM | |
| SCHEMBL11973986 | 0.91 | AHCY (0.54) | AHCYNOTUM | |
| SCHEMBL11975756 | 0.88 | AHCY (0.47) | AHCYNOTUM | |
| SCHEMBL1026285 | 0.85 | AHCY (0.40) | AHCYNOTUM | |
| SCHEMBL11973989 | 0.85 | AHCY (0.51) | AHCY | |
| SCHEMBL11975731 | 0.85 | AHCY (0.56) | AHCYNOTUM | |
| SCHEMBL11975738 | 0.83 | AHCY (0.46) | AHCYNOTUM | |
| SCHEMBL11975206 | 0.83 | AHCY (0.56) | AHCYNOTUM | |
| SCHEMBL13652568 | 0.83 | AHCY (0.54) | AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| WO-2009125853-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | 田辺三菱製薬株式会社 (JP) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | AHCY 4108/4885NOTUM 3617/4885 |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | BHMT, CBS, BHMT2 | AHCY 4/4885NOTUM 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.